The packet lists SOD1, C9ORF72, FUS and TARDBP as genes associated with ALS, and the condition can therefore result from variants in several different genes. The packet does not supply ClinGen validity classifications for these genes and does not supply a structured inheritance field for the disease. Its subtype list distinguishes familial ALS from sporadic ALS. The attached expert-review chapter on the TARDBP-related form states that this form is inherited in an autosomal dominant manner and that about half of individuals diagnosed have an affected parent while about half are simplex cases, meaning the only known affected family member. That chapter also states that missense variants in TARDBP show high penetrance and that males and females are similarly affected. It reports that TARDBP variants are found in about 3% to 4% of people with a family history of ALS or frontotemporal dementia and in about 1.5% of those without such a history. These statements are specific to TARDBP and are not certified in the packet for the other listed genes.

The packet does not list diagnostic methods for ALS overall. The attached expert-review chapter on the TARDBP-related form states that no consensus clinical diagnostic criteria have been published for that form. It describes the diagnosis of the TARDBP-related form as established when a heterozygous pathogenic or likely pathogenic variant in TARDBP is identified by molecular genetic testing, and describes the condition as clinically indistinguishable from ALS and frontotemporal dementia due to other causes. The chapter describes multigene panels or comprehensive genomic testing as the approaches used, and notes that variants of uncertain significance cannot confirm or rule out the diagnosis. It also states that a lack of known family history does not preclude the diagnosis. Brain MRI is described there as usually normal in the ALS presentation, although corticospinal tract high signal intensity may be seen. The chapter lists conditions considered in the differential diagnosis, including compressive cervical myelopathy, hereditary spastic paraplegia, chronic inflammatory polyradiculoneuropathy, multifocal motor neuropathy, inclusion body myositis, spinal muscular atrophy IV and, for behavioral presentations, psychiatric disorders.

FDA records in the packet list five approved products with an active market status. QALSODY (tofersen) was approved in April 2023, and the attached expert-review text notes that tofersen has been approved by the FDA for SOD1-related ALS-FTD and that no approved antisense oligonucleotide therapies exist for the TARDBP-related form. RADICAVA ORS (edaravone) was approved in May 2022, TIGLUTIK (riluzole) in September 2018, RADICAVA (edaravone) in May 2017, and RILUTEK in December 1995. The packet does not state indications or eligibility criteria for these products. The expert review states that there is no cure for the TARDBP-related form and that supportive care is central. It describes multidisciplinary care involving neurology, physical and occupational therapy, speech-language therapy, dietetics, respiratory care, psychology, social work, genetic counseling, palliative care and specialized nursing. Supportive measures it lists include mobility and daily-living equipment, augmentative communication devices for dysarthria, swallowing techniques and gastrostomy tube feeding for dysphagia, and assisted ventilation, noninvasive at first and progressing to tracheostomy when necessary, for respiratory function. For other manifestations such as spasticity, muscle cramps, sialorrhea and pseudobulbar affect, the review lists medication classes and specific agents. The review also notes that edaravone is not approved worldwide. The packet includes a larger set of orphan-designated products, and the packet treats designation as separate from approval. The packet also lists two patient assistance programs for ALS, one for premium and copay support and one for travel and lodging assistance, both marked as accepting enrollment.

The packet does not supply a natural history or survival statement for ALS overall. The attached expert-review chapter on the TARDBP-related form states that life expectancy is highly variable and is mainly associated with an individual's clinical features. It also describes progressive worsening of behavioral features in the rare pure frontotemporal dementia presentation. No survival figures are certified in the packet.

The packet reports active ClinicalTrials.gov registration for ALS, with a large number of records, and includes detailed records for ten studies. Among them, NCT07855211 is a phase 1 study sponsored by Biogen of BIIB147 that is not yet recruiting. NCT06726577 is a recruiting phase 1 study of TP04HN106 sponsored by Talengen Institute of Life Sciences. NCT07204977 is a recruiting phase 1 study of acamprosate in C9orf72 repeat expansion ALS sponsored by NINDS. NCT04220190 is a recruiting phase 2 study of RAPA-501 therapy sponsored by Rapa Therapeutics, and NCT05407324 is a phase 2 study of dazucorilant sponsored by Corcept Therapeutics that is active but not recruiting. Other listed records include a brain-machine interface system study (NCT05936619), a metabolism and nutrition study in motor neuron disease (NCT07851714), and a study of early detection of respiratory impairment (NCT07844590). A trial title does not indicate that an intervention is effective. The packet's intervention summary lists drug therapy, biologic therapy, medical devices and other interventions, and notes the presence of gene therapy trials. Its publication digest classifies 1,401 papers, with basic science and preclinical work as the dominant type. Orphan designations for ALS in the packet include products such as an adeno-associated virus encoding an anti-SOD1 microRNA, and these designations are not approvals.